7-(benzyloxy)-6-d3-methoxyquinazolin-4(3H)-one | 1174397-22-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(benzyloxy)-6-d3-methoxyquinazolin-4(3H)-one
• 英文别名: 7-phenylmethoxy-6-(trideuteriomethoxy)-3H-quinazolin-4-one
• CAS: 1174397-22-8
• 化学式: C₁₆H₁₄N₂O₃
• 分子量: 285.275
• InChiKey: ZCUFFSHMOAEEIL-FIBGUPNXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• VANDETANIB DERIVATIVES
  申请人：Tung Roger

  公开号：US20110117084A1

  公开（公告）日：2011-05-19

  This invention relates to novel quinazoline derivatives and their acceptable acid addition salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibitory activity against the VEGF receptor tyrosine kinase.

  本发明涉及新型喹噁啉衍生物及其可接受的酸盐。本发明还提供了包含本发明化合物的组合物，并且使用这种组合物治疗通过抑制VEGF受体酪氨酸激酶活性有益治疗的疾病和病症的方法。
• US8609673B2
  申请人：——

  公开号：US8609673B2

  公开（公告）日：2013-12-17
• [EN] QUINAZOLINE COMPOUNDS AND METHODS OF TREATING CANCER<br/>[FR] COMPOSÉS DE QUINAZOLINE ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2009094211A1

  公开（公告）日：2009-07-30

  This invention relates to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of angiogenesis and vascular endothelial growth factor receptor (VEGF) kinases.
• [EN] VANDETANIB DERIVATIVES<br/>[FR] DÉRIVÉS DE VANDETANIB
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2009094210A1

  公开（公告）日：2009-07-30

  This invention relates to novel quinazoline derivatives and their acceptable acid addition salts. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by inhibitory activity against the VEGF receptor tyrosine kinase.